Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02401945 · ClinicalTrials.gov registry record · Phase 2
A Safety and Efficacy Study of DE-120 Injectable Solution for Age-related Macular Degeneration
A Phase 2 study, sponsored by Santen.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT02401945 is a Phase 2 study that has completed, run by Santen. The registered enrollment target is 16 participants.
The verdict
NCT02401945, a Phase 2 study, has completed, sponsored by Santen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the safety and efficacy of intravitreal (IVT) administration of DE-120 in subjects with treatment-naive active subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).
Interventions
- DRUG Aflibercept
- DRUG DE-120
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2015-04 |
| Est. Completion | 2016-10-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02401945
The ClinicalTrials.gov registry entry for NCT02401945 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Santen, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Aflibercept is the first listed.
NCT02401945 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02401945 about?
NCT02401945 is a clinical study titled "A Safety and Efficacy Study of DE-120 Injectable Solution for Age-related Macular Degeneration". The purpose of the study is to evaluate the safety and efficacy of intravitreal (IVT) administration of DE-120 in subjects with treatment-naive active subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).
What is the current status of trial NCT02401945?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2015-04. Estimated completion is 2016-10-31.
What interventions are being tested in trial NCT02401945?
The interventions under investigation include: Aflibercept (DRUG), DE-120 (DRUG).
Who is sponsoring clinical trial NCT02401945?
This trial is sponsored by Santen, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.